Skip to main content
Quantum Genomics logo

Quantum Genomics — Investor Relations & Filings

Ticker · ALQGC ISIN · FR0011648971 LEI · 969500TFCD8K9RPM9K97 PA Manufacturing
Open in API
Filings indexed 341 across all filing types
Latest filing 2025-10-29 Delisting Announcement
Country FR France
Listing PA ALQGC

About Quantum Genomics

https://quantum-genomics.com/

Quantum Genomics is a biopharmaceutical company focused on developing a new class of medications for cardiovascular diseases with high unmet medical needs, such as difficult-to-treat or resistant hypertension and heart failure. The company's core research is based on a breakthrough therapeutic approach involving the inhibition of Brain Aminopeptidase A (BAPA). Its lead drug candidate, firibastat, is a first-in-class BAPA inhibitor designed to offer a novel treatment mechanism for managing these conditions.

Recent filings

Filing Released Lang Actions
Liquidation judiciaire simplifiée de la société QUANTUM GENOMICS SA
Delisting Announcement Classification · 100% confidence The document is an official announcement regarding the 'liquidation judiciaire simplifiée' (simplified judicial liquidation) of Quantum Genomics SA, as ordered by the Paris Commercial Court. It explicitly states that there will be no resumption of trading and that Euronext is expected to proceed with the delisting of the shares. Since the primary purpose is to inform the market of the company's liquidation and the impending removal of its stock from the exchange, it falls under the Delisting Announcement category.
2025-10-29 French
Quantum Genomics annonce avoir saisi le Tribunal des activités économiques de Paris en vue de l'ouverture d'une procédure de liquidation judiciaire
Legal Proceedings Report Classification · 95% confidence The document is a press release from Quantum Genomics announcing that the company has filed for judicial liquidation (liquidation judiciaire) with the Paris Commercial Court due to an inability to secure financing and ongoing suspension of its stock. This constitutes a significant legal and regulatory event regarding the company's status. While it mentions potential delisting, the primary subject is the legal proceeding of liquidation, which fits best under 'Legal Proceedings Report' (LTR) as it details the company's legal action and court involvement.
2025-07-03 French
Report de l'Assemblée Générale Mixte du 30/06/2025
AGM Information Classification · 98% confidence The document explicitly mentions 'Report de l'Assemblée Générale Mixte' (Report of the Combined General Meeting) and discusses the postponement of this meeting, which was intended to approve the accounts for the year ended December 31, 2024. It also mentions the process for announcing the new date via press release and official gazettes (BALO). This content directly relates to the Annual General Meeting (AGM) proceedings and materials, fitting the definition for AGM Information (AGM-R). Although it discusses the postponement, the core subject is the AGM itself.
2025-06-13 French
Quantum Genomics publishes its 2024 annual financial statements and announces a change in listing sponsor
Report Publication Announcement Classification · 98% confidence The document is explicitly titled "Quantum Genomics publishes its 2024 annual financial statements and announces a change in listing sponsor." It contains key financial tables for the year 2024, including Net Income and EBITDA, and explicitly mentions the "2024 annual financial report" which includes the management report, governance report, and statutory auditors' reports. This strongly indicates the core content relates to the full annual financial performance. However, the document is structured as a press release announcing the *availability* of the annual financial report, rather than the report itself (which is usually much longer and filed as a 10-K or similar comprehensive filing). The text states: "In accordance with Euronext Growth Paris regulations, Quantum Genomics today announces the availability to the public and filing with the French Financial Markets Authority (AMF) of its annual financial report as of December 31, 2024." This aligns perfectly with the definition of a Report Publication Announcement (RPA): "Announcement regarding the timing, release, or publication of company reports (often stating the report is attached or available on the website).". While it contains the results (ER/IR content) and mentions the components of an Annual Report (10-K), the primary function of this specific document is to announce that the full annual report is now available. Given the length (5483 chars) and the explicit announcement structure, RPA is the most accurate classification based on the provided rules, especially Rule 2 (Menu vs Meal).
2025-04-30 English
Quantum Genomics publie ses comptes annuels 2024 et annonce un changement de listing sponsor
Delisting Announcement Classification · 99% confidence The document explicitly states: "Quantum Genomics publie ses comptes annuels 2024" (Quantum Genomics publishes its 2024 annual accounts) and later confirms the "Mise à disposition du rapport financier annuel 2024" (Making available of the 2024 annual financial report). It includes a detailed table of annual financial results for 2024 and 2023, and mentions that the report includes the management report, corporate governance report, and annual accounts certified by auditors. This content strongly indicates the release of the full annual financial report, which corresponds to the 10-K definition (Official yearly report covering company activity and full financial performance), even though the company is listed on Euronext Growth and the document is in French. The length (7795 chars) is substantial, suggesting it is the report summary/release, not just a brief announcement (RPA).
2025-04-30 French
Quantum Genomics fait un point sur sa situation
Delisting Announcement Classification · 99% confidence The document is a press release dated April 8, 2025, providing an update on the company's operational status, specifically concerning the suspension of its stock listing on Euronext and the ongoing search for a reverse acquisition partner. It discusses financial status, debt obligations, and the expected publication date for the 2024 annual accounts (April 30, 2025). Since this is a general operational and financial status update released via a press release, and it is not the full Annual Report (10-K), a specific financial release (ER), or a formal regulatory filing detailing a specific event like a dividend or share transaction, it best fits the general 'Regulatory Filings' (RNS) category as a miscellaneous corporate announcement, or potentially a Management Report (MDA) if it were more analytical. Given the nature of providing a status update on critical corporate events (listing suspension, search for a partner) outside of the standard periodic reports, RNS is the most appropriate general classification for this type of press release update.
2025-04-08 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.